Clinical Trials · NCT02713477
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 20
- Start date
- Apr 2016
- Locations
- 1 site, Japan
- Primary endpoint
- Measurement of plasma glucose concentrations